Ads
related to: vrtx stock buy or sell
Search results
Results from the WOW.Com Content Network
In this article you are going to find out whether hedge funds think Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a good investment right now. We like to check what the smart money thinks ...
Price Action: VRTX stock is down 13.4% at $387.37 at last check Thursday. Read Next: Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges.
Vertex Pharmaceuticals' (NASDAQ:VRTX) stock is up by 5.4% over the past three months. Given its impressive performance...
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
In 2012 ivacaftor was designated as an orphan drug, identifying cystic fibrosis as affecting fewer than 200,000 people in the United States.On 31 January 2012, Vertex gained FDA approval [22] of the first drug, Kalydeco, [23] to treat the underlying cause of cystic fibrosis rather than the symptoms, in patients 6 years or older who have the G551D gene mutation.
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that ...
New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving sales of Vertex's (VRTX) triple therapy cystic fibrosis drug, Trikafta/Kaftrio higher.
For premium support please call: 800-290-4726 more ways to reach us
Ads
related to: vrtx stock buy or sell